The company said Ivosidenib tablets are indicated for patients with newly diagnosed Acute Myeloid Leukemia (AML) as monotherapy in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Zydus Lifesciences announced on Thursday that it has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic Azilsartan Medoxomil tablets, which are used to treat high blood pressure. The USFDA's tentative approval covers Azilsartan Medoxomil tablets in strengths of 40 mg and 80 mg.
A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale of this innovative product, expected to revolutionise the insulin market. While further studies are required, doctors anticipate improved patient compliance with this new treatment option.
Aurigene to Provide Cell Therapy Discovery Services
Abbott and YRGCARE, a leading non-profit offering non-stigmatizing, high-quality services to those with or at risk for HIV (Human Immunodeficiency Virus), opened two new facilities dedicated to helping stop the spread of HIV. The initiative aims to transform the lives of over 2500 people in these cities over the next year by taking a holistic approach for those who have or are at-risk for HIV and other known or emerging infectious diseases.
Orchid Pharma Limited (Orchid Pharma) announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. Chennai-based Orchid Pharma has partnered with Cipla Limited (Cipla) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
Zydus Lifesciences Limited and Dr. Reddy's Laboratories, a global pharmaceutical company, announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India. Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC).
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)